VAP-1 Antibody (E-10): sc-373924

VAP-1 Antibody (E-10) is a mouse monoclonal IgG2a kappa light chain antibody that detects VAP-1 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). VAP-1 (E-10) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. VAP-1, or vascular adhesion protein-1, plays a crucial role in immune response by facilitating lymphocyte adhesion to vascular endothelium, which is essential for migration from bloodstream to lymphoid tissues and inflammation sites. VAP-1 is a type II transmembrane sialoglycoprotein predominantly expressed on endothelial cells during inflammatory conditions, where expression significantly increases. VAP-1 features a single transmembrane domain and contains N- and O-glycosylation sites within its extracellular domain, vital for function. VAP-1 exists mainly as a homodimer and serves dual roles as both a monoamine oxidase and adhesion molecule. Proper glycosylation of VAP-1 is critical for mediating lymphocyte adhesion, thereby influencing lymphocyte recirculation during immune responses. VAP-1 is expressed in various smooth muscle cells, although not facilitating lymphocyte binding in these cells, instead involving deamination of primary amines. Elevated soluble VAP-1 levels in circulation have been associated with inflammatory liver diseases, highlighting potential as a biomarker for such conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VAP-1 Antibody (E-10) References:

1. Human vascular adhesion protein-1 (VAP-1) plays a critical role in lymphocyte-endothelial cell adhesion cascade under shear.  |  Salmi, M., et al. 2000. Circ Res. 86: 1245-51. PMID: 10864915
2. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1).  |  Koskinen, K., et al. 2004. Blood. 103: 3388-95. PMID: 14726375
3. Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner.  |  Abella, A., et al. 2004. Diabetologia. 47: 429-438. PMID: 14968297
4. The release of soluble VAP-1/SSAO by 3T3-L1 adipocytes is stimulated by isoproterenol and low concentrations of TNFalpha.  |  García-Vicente, S., et al. 2005. J Physiol Biochem. 61: 395-401. PMID: 16180338
5. Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis.  |  Airas, L., et al. 2006. J Neuroimmunol. 177: 132-5. PMID: 16806498
6. Ischemia-reperfusion injury is attenuated in VAP-1-deficient mice and by VAP-1 inhibitors.  |  Kiss, J., et al. 2008. Eur J Immunol. 38: 3041-9. PMID: 18991279
7. Circulating form of human vascular adhesion protein-1 (VAP-1): decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis.  |  Toiyama, Y., et al. 2009. J Surg Oncol. 99: 368-72. PMID: 19204971
8. ω-(5-Phenyl-2H-tetrazol-2-yl)alkyl-substituted glycine amides and related compounds as inhibitors of the amine oxidase vascular adhesion protein-1 (VAP-1).  |  Pöstges, T., et al. 2024. Bioorg Med Chem. 98: 117558. PMID: 38142562
9. Vascular adhesion protein 1 (VAP-1) mediates lymphocyte subtype-specific, selectin-independent recognition of vascular endothelium in human lymph nodes.  |  Salmi, M., et al. 1997. J Exp Med. 186: 589-600. PMID: 9254657

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VAP-1 Antibody (E-10) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-VAP-1 Antibody (E-10) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VAP-1 Antibody (E-10) Specifications

Alternate Product Name: VAP-1

Product Clone Name: E-10

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 703-739

Epitope Target: VAP-1

Epitope Species: human

Product Reactivity/Detection: VAP-1 and placenta amine oxidase

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for VAP-1 Antibody (E-10): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin

The preferred VAP-1 antibody is VAP-1 Antibody (A-8): sc-166713.